The effect of collecting appears, a large number of well-known pharmaceutical companies compete to reduce sales costs

As of October 22, a total of 118 pharmaceutical and biological enterprises in A-shares have issued earnings forecasts for the first three quarters of 2020, more than half of which are expected.
, in addition to some segments of the company ushered in high performance growth, more notably, many well-known pharmaceutical companies are scrambling to cut sales costs.
details of the use of sales expenses disclosed by a number of listed companies, holding and sponsoring academic conferences, professional training for sales staff, travel expenses, etc., are the main contents.
, Zhejiang Huahai Pharmaceuticals released its third-quarter report.
reported revenue of about Rmb4,871m for the January-September period, up 21.41 per cent from the same period in 2019, while net profit rose 64.23 per cent year-on-year.
, third-quarter revenue was 1.565 billion yuan, up 15.20% year-on-year.
But while performance grew, Huahai Pharmaceuticals' third-quarter sales expenses fell 30.98 percent year-on-year to just 207 million yuan, another sharp drop after Huahai Pharmaceuticals' sales expenses fell 25.79 percent year-on-year in 2019.
for the performance of the big increase, sales costs, Huahai Pharmaceuticals said, this is mainly due to the "collection" of good effects and the European sand bile raw materials to lift the ban.
It is understood that in the first three batches of national mining, Huahai Pharmaceuticals has Reinopri tablets, chlorosatan tablets, Ebersatan tablets, lipe ketone tablets, hydrochloric acid paroxetine tablets, Ebersatan hydrochlorochlorine tablets, Fusinpri sodium tablets, oxylitan tablets, such as many products selected, and many of the annual sales of hundreds of millions of dollars of large varieties.
, Huahai Pharmaceuticals is not an example of pharmaceutical companies cutting sales costs, from the third quarter has been issued by the listed companies, cutting sales costs is becoming more and more common.
such as Shenzhen Xinlitai's third-quarter sales expenses of about 450 million yuan, a decrease of 38.60 percent year-on-year.
's third-quarter sales expenses were 648 million yuan, down 19.26 percent year-on-year, and the overall decline in the first three quarters was about 12.12 percent.
, the parent company of The Kun Pharmaceutical Group, also fell sharply in the third quarter, to 58.23 per cent, and in the first three quarters it fell by more than 60 per cent.
Said in its third-quarter 2020 report that sales expenses decreased by 93.4355 million yuan, or 52.26 percent, from a year earlier, mainly due to a decrease in service charges for the promotion of finished drugs.
In addition to domestic companies, from the perspective of multinational pharmaceutical companies, Pfizer's Pfizer (Atovastatin), Lysin Hi (benzodiaxane chloride) and other drivers of business by the impact of volume procurement, such as slowing growth, its generics sector revenue continued to decline, in the fourth quarter of 2019 fell by 32%.
the first quarter of 2020, revenues in the sector fell 37 per cent year-on-year, pulling Pfizer directly off the throne.
from the above three-quarter report, the impact of the epidemic and volume procurement is the main reason affecting the cost of drug sales.
, volume procurement is the main long-term factor.
under the implementation of the volume of procurement, the selection of no promotion, no promotion is useless, pharmaceutical companies to reduce sales costs is not only an inevitable result, but also shows the trend of enterprise transformation.
Industry insiders believe that in the future, in addition to the continuous expansion of the volume of procurement, with the medical insurance catalog, the adjustment of the base drug catalog, biological drugs (including insulin), traditional Chinese medicine should also be included in the volume of procurement and other policy effects, will further force the Chinese pharmaceutical market to intensify the situation.
the impact of this, drug companies' strategies, personnel adjustment will be more and more frequent.